Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
This trial aims to prospectively assess the safety and efficiency of Fluzoparib in metastatic non-clear cell renal cell carcinoma
Renal Cell Carcinoma
DRUG: Fluzoparib
objective response rate（ORR）, the proportion of patients with CR, PR, and SD in the group（RECIST1.1）, three months
radiographic progression free survival（rPFS）, the time frame from the first day of fluzoparib to the date of radiographic confirmed progressive disease or death which one occurrs first, six months|overall survival（OS）, the time frame from the first day of fluzoparib to the date of death the time frame from the first day of apatinib to the date of death the time frame from the first day of apatinib to the date of death the time frame from the first day of apatinib to the date of death the time frame from the first day of apatinib to the date of death, eighteen months|time to progression（TTP）, the time frame from the first day of fluzoparib to the date of confirmed progressive, six months|AE, Number of Adverse Events, Grade 3 or higher as defined by Common Terminology Criteria for Adverse Events (CTCAE) v5.0, 2 years
This trial aims to prospectively assess the safety and efficiency of Fluzoparib in metastatic non-clear cell renal cell carcinoma